Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study expl...Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study explored the clinicopathological characteristics of the G719 X mutation and investigated the efficacy of EGFR-tyrosine kinase inhibitor(TKI) treatment and chemotherapy in patients with the G719 X mutation; the survival rate after these different treatment modalities were then analyzed in order to provide evidence for clinical treatment.Methods Clinical data of 41 patients with the G719 X mutation admitted in the Beijing Chest Hospital, Capital Medical University from September 2014 to July 2018, were collected and the EGFR mutations were detected by amplification refractory mutation system-polymerase chain reaction(ARMS-PCR). The clinicopathological characteristics of the G719 X mutation were analyzed, and the relationship among the G719 X mutation, the efficacy of different treatment modalities, and the progression-free survival(PFS) was analyzed. Results Of the 41 cases, 24(58.5%) were G719 X single mutations and 17(41.5%) were compound mutations, including G719 X/S768 I, G719 X/L861 Q, G719 X/19 del, and G719 X/c-Met compound mutation. The objective response rate(ORR) of first-line EGFR-TKI therapy was 50%(6/12), the disease control rate(DCR) was 83.3%(10/12), and the median PFS(mPFS) was 9 months. After resistance to EGFR-TKI in the previous treatment, the ORR(71.4%, 5/7) and DCR(100%, 7/7) were still high following EGFR-TKIs, by an mPFS of 8 months. The ORR of chemotherapy was 33.3%(2/6), the DCR was 100%(6/6), and the mPFS was 6 months. Conclusion G719 X is an uncommon mutation of the EGFR gene and is sensitive to many EGFR-TKIs. It can be treated with the second-or third-generation EGFR-TKIs after resistance to the first-generation EGFR-TKIs. G719 X mutation also showed favorable effect to chemotherapy.展开更多
The different formats of codec stream carried in the radio access network and the core network make the double speech encoding/decoding necessary, which degrades the speech quality. Accordingly, codec negotiation tech...The different formats of codec stream carried in the radio access network and the core network make the double speech encoding/decoding necessary, which degrades the speech quality. Accordingly, codec negotiation technologies are necessary for unifying encoding/ decoding in the whole process. Transcoder Free Operation (TrFO), Tandem Free Operation (TFO), and network quality deciding technology are the leading codec negotiation technologies. The TrFO is a mechanism for optimum selection during the establishment of a call. It tries to establish connection between User Equipment (UE) without Transcoder (TC). Its successful fulfillment enables the efficient utilization of bandwidth. The TFO, a standby technology of TrFO, is the negotiation technology of an in-band codec. With it, the user codec stream is free from the compression and decompression by the voice codec, and the quality of voice can accordingly be improved. The network-quantity deciding technology adopts G.711 or G.729 flexibly according to the number of accessed calls. This allows the access of new calls while won’t increase the load of network too much.展开更多
ITU-T G. 729 is the primarily recommended speech codec by H. 323 standard. This paper describes how to implement G. 729 codec in IP telephony gateway, and goes deep into the programming skills on TMS320C6201 DSP and o...ITU-T G. 729 is the primarily recommended speech codec by H. 323 standard. This paper describes how to implement G. 729 codec in IP telephony gateway, and goes deep into the programming skills on TMS320C6201 DSP and optimizing methods of program code to reduce the speech processing delay time of G. 729 codec. Due to adopting these optimizing methods and programming skills, we have implemented a high-speed speech codec that can process concurrently 20 voice channels with single TMS320C6201 chip in IP telephony gateway. Finally, the paper analyzes the performance results of ITU-T G. 729 codec based on TMS320C6201.展开更多
文摘Objective G719 X is the most frequently seen uncommon mutation of the epidermal growth factor receptor(EGFR) gene, which is a point mutation at exon 18 with three common subtypes, G719 A/G719 C/G719 S. This study explored the clinicopathological characteristics of the G719 X mutation and investigated the efficacy of EGFR-tyrosine kinase inhibitor(TKI) treatment and chemotherapy in patients with the G719 X mutation; the survival rate after these different treatment modalities were then analyzed in order to provide evidence for clinical treatment.Methods Clinical data of 41 patients with the G719 X mutation admitted in the Beijing Chest Hospital, Capital Medical University from September 2014 to July 2018, were collected and the EGFR mutations were detected by amplification refractory mutation system-polymerase chain reaction(ARMS-PCR). The clinicopathological characteristics of the G719 X mutation were analyzed, and the relationship among the G719 X mutation, the efficacy of different treatment modalities, and the progression-free survival(PFS) was analyzed. Results Of the 41 cases, 24(58.5%) were G719 X single mutations and 17(41.5%) were compound mutations, including G719 X/S768 I, G719 X/L861 Q, G719 X/19 del, and G719 X/c-Met compound mutation. The objective response rate(ORR) of first-line EGFR-TKI therapy was 50%(6/12), the disease control rate(DCR) was 83.3%(10/12), and the median PFS(mPFS) was 9 months. After resistance to EGFR-TKI in the previous treatment, the ORR(71.4%, 5/7) and DCR(100%, 7/7) were still high following EGFR-TKIs, by an mPFS of 8 months. The ORR of chemotherapy was 33.3%(2/6), the DCR was 100%(6/6), and the mPFS was 6 months. Conclusion G719 X is an uncommon mutation of the EGFR gene and is sensitive to many EGFR-TKIs. It can be treated with the second-or third-generation EGFR-TKIs after resistance to the first-generation EGFR-TKIs. G719 X mutation also showed favorable effect to chemotherapy.
文摘The different formats of codec stream carried in the radio access network and the core network make the double speech encoding/decoding necessary, which degrades the speech quality. Accordingly, codec negotiation technologies are necessary for unifying encoding/ decoding in the whole process. Transcoder Free Operation (TrFO), Tandem Free Operation (TFO), and network quality deciding technology are the leading codec negotiation technologies. The TrFO is a mechanism for optimum selection during the establishment of a call. It tries to establish connection between User Equipment (UE) without Transcoder (TC). Its successful fulfillment enables the efficient utilization of bandwidth. The TFO, a standby technology of TrFO, is the negotiation technology of an in-band codec. With it, the user codec stream is free from the compression and decompression by the voice codec, and the quality of voice can accordingly be improved. The network-quantity deciding technology adopts G.711 or G.729 flexibly according to the number of accessed calls. This allows the access of new calls while won’t increase the load of network too much.
基金Supported by the National Natural Science Foundation of China under grant!69773046
文摘ITU-T G. 729 is the primarily recommended speech codec by H. 323 standard. This paper describes how to implement G. 729 codec in IP telephony gateway, and goes deep into the programming skills on TMS320C6201 DSP and optimizing methods of program code to reduce the speech processing delay time of G. 729 codec. Due to adopting these optimizing methods and programming skills, we have implemented a high-speed speech codec that can process concurrently 20 voice channels with single TMS320C6201 chip in IP telephony gateway. Finally, the paper analyzes the performance results of ITU-T G. 729 codec based on TMS320C6201.
